Clinical Benefits of Following Therapy after Anti-HER2 Standard Therapy for HER2-positive, Unresectable and/or Metastatic Breast Cancer: a Retrospective Registry Study (KBCSG-TR 1917)

Clinical Benefits of Following Therapy after Anti-HER2 Standard Therapy for HER2-positive, Unresectable and/or Metastatic Breast Cancer: a Retrospective Registry Study (KBCSG-TR 1917) - Clinical Benefits of Following Therapy after Anti-HER2 Standard Therapy for HER2-positive, Unresectable and/or Metastatic Breast Cancer: a Retrospective Registry Study (KBCSG-TR 1917)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038296

Enrollment

100

Registered

2019-10-15

Start date

2019-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive, unresectable and/or metastatic breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Women over 20 years old at the start of the following therapy after T-DM1 treatment 2)Has pathologically documented HER2-positive, unresectable or metastatic breast cancer 3)Has received at least one following therapy(Anti-HER2 therapy, other targeted therapy, chemotherapy and/or endocrine therapy) after T-DM1 treatment for HER2-positive unresectable or metastatic breast cancer betweeen Jan 1st, 2014 and Dec 31st, 2018

Exclusion criteria

Exclusion criteria: 1) Has received any investigational new drug or any approved drug without breast cancer indication in any clinical trial as the following therapy after T-DM1 treatment 2) Has declined to participate in this study before the database has been locked

Design outcomes

Primary

Measure	Time frame
1.rwPFS:Real world progression-free survival 2.TTF:Time to treatment failure 3.OS:Overall survival 4.ORR:Objective response rate 5.CBR:Clinical benefit rate	—

Countries

Japan

Contacts

Public ContactTakahiro Nakayama

NPO the Supporting Center for Clinical Research and Education Kinki Breast Cnacer Study Group-Translational Research

taqnakayama@hotmail.com06-6897-5037

Outcome results